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CD163 expression in leukemia cutis
Background: Proper diagnosis of myeloid leukemia cutis (LC) is of
great clinical importance but can be difficult because no single
immunohistochemical marker is adequately sensitive or specific for
definitive diagnosis. Thus, a broader panel of markers is often desirable.
CD163 is highly specific for normal and neoplastic cells of the
monocyte/histiocyte lineage. In this study, we examined the value of
CD163 in the diagnosis of acute myeloid LC.
Methods: A total of 34 cases, including 18 cases of myelomonocytic or
monocytic LC, 10 cases of myeloid LC without monocytic component
and 6 cases of acute lymphoblastic leukemia/lymphoma (ALL), were
stained with CD163.
Results: CD163 was expressed in 8 of 18 (44%) of myelomonocytic or
monocytic LC and 1 of 10 (10%) of other myeloid LC, but in none of
the ALL cases (0/6). CD163 was highly specific (90%) for myeloid LC
with a monocytic component, but showed low sensitivity in the
diagnosis of both myeloid LC in general (24%) and myeloid LC with a
monocytic component (44%).
Conclusions: Our results suggest that CD163 has utility as a specific
marker for myeloid LC in conjunction with currently used
immunohistochemical stains, but should not be used alone for diagnosis.
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Acute myeloid leukemia (AML) may form tumor
masses in extramedullary sites, with skin being one
of the most common sites.1 The involvement of skin
by myeloid leukemic infiltrate, or myeloid leukemia
cutis (LC), may precede the appearance of systemic
disease, occur concurrently with systemic AML, or
herald disease recurrence in treated patients.1,2. In
addition, the onset of myeloid LC may be a sign that
blastic transformation of a pre-existing myelodys-
plastic syndrome or myeloproliferative neoplasm
(previously known as chronic myeloproliferative dis-
ease) is occurring.
Recognition of myeloid LC is clinically essential,
yet sometimes poses diagnostic difficulties. Particu-
larly, the diagnosis of LC in the absence of known
systemic disease (aleukemic LC), which occurs in
7% of cases is challenging.2 Clinical manifestations
of myeloid LC are non-specific and may present
as erythematous rash, urticaria, purpura, plaques or
nodules. Histopathologically, early myeloid LC may
involve the dermis in an angiocentric pattern, with or
without infiltration between collagen bundles; more
developed lesions show diffuse dermal infiltrate of
immature granulocytes or monocytes, sparing the
epidermis.2 In many cases, however, histopathologic
features alone are not sufficient to rule out other
entities, such as cutaneous lymphoproliferative pro-
cesses or acute lymphoblastic leukemia/lymphoma
(ALL).3 Therefore, immunophenotyping is routinely
employed for accurate diagnosis of LC. Useful mark-
ers include CD68 (KP1 or PG-M1), myeloperoxidase
(MPO), CD117, CD43 and lysozyme, as well as B-cell
or T-cell markers. CD68, one of the most sensitive
markers, may also stain a variety of other tumor types,
including melanomas and carcinomas.4,5 MPO is
more specific for myeloid lineage, but reports vary
regarding its sensitivity, particularly in LC with
monocytic differentiation.1– 3 Rarely, myeloid LC
may display aberrant expression of B-cell or T-cell
markers.3 In challenging cases, a more complete
armamentarium of immunohistochemical markers is
desirable in order to increase diagnostic accuracy.
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CD163 is a transmembrane glycoprotein in the
class B scavenger receptor cysteine-rich (SRCR)
family. CD163 exhibits high-affinity binding and
endocytosis of the haptoglobin–hemoglobin com-
plex, thus serving as the primary effector of hap-
toglobin–hemoglobin clearance from circulation.6
CD163 expression is largely restricted to the mono-
cyte/macrophage lineage.4,5 In bone marrow and
lymph nodes, CD163 immunoreactivity is detected in
AMLs with monocytic differentiation. Carcinomas,
most melanomas and B-cell or T-cell lymphomas
were found to be negative for CD163,4,5,7,8 although
its expression has been reported in 29% of desmo-
plastic melanomas.9
Few reports have examined the expression of
CD163 in myeloid LC, and none evaluated its speci-
ficity in distinguishing myeloid LC from cutaneous
ALL.4,10,11 Because of its specificity for the mono-
cytic lineage and its expression in bone marrow and
extramedullary sites other than skin, we explored the
expression of CD163 in myeloid LC. We hypothe-
sized that CD163 would be useful as a specific marker
for myeloid LC with monocytic differentiation.
Materials and methods
After obtaining approval from the University of
Michigan Institutional Review Board for human sub-
ject research, 34 consecutive cases of LC were iden-
tified through a retrospective search of the pathology
database from the Department of Pathology at the
University of Michigan. All tumors examined are
listed in Table 1.
Table 1. CD163 staining results for LC in comparison to other markers
Case Diagnosis CD163 CD68 Lysozyme MPO CD43
1 AML-M0 Negative ND ND ND Positive
2 AML-M1 Negative ND ND Rare positive ND
3 AML-M1 Negative ND Negative Focal positive Positive
4 AML-M1 Negative ND Negative Rare positive Positive
5 AML-M1 Negative Negative Negative Negative Weak positive
6 AML-M2 >50% ND ND ND Positive
7 AML-M2 Negative ND Positive Positive Positive
8 AML-M2∗ Negative ND ND ND ND
9 AML-M3v† Negative ND ND ND ND
10 AML-M4 >50% Positive Subset positive Subset positive Positive
11 AML-M4 >50% Positive Positive Subset positive Positive
12 AML-M4 10–50% ND ND Subset positive Positive
13 AML-M4 10–50% ND Subset positive Positive Positive
14 AML-M4 Negative ND ND Rare positive Positive
15 AML-M4 Negative Positive Negative Negative Positive
16 AML-M4 Negative Positive Positive Rare positive Positive
17 AML-M4 Negative Positive Positive Subset positive Positive
18 AML-M4 Negative ND Subset positive Subset positive Positive
19 AML-M4 Negative Weak positive ND Negative Positive
20 AML-M4 Negative Positive Subset positive ND ND
21 AML-M5b >50% ND Positive Subset positive Positive
22 AML-M5 10–50% ND Negative Negative Positive
23 AML-M5 10–50% Weak positive Positive Rare positive Positive
24 AML-M5 Negative Negative Subset positive Positive Positive
25 AML-M5b Negative ND ND ND ND
26 AML-M5b Negative Weak positive Positive Rare positive Positive
27 AML-M4/M5 10–50% Negative Positive Negative Positive
28 AML-M6 Negative ND ND ND ND
29 T-ALL Negative ND ND ND ND
30 Precursor B-ALL Negative ND Subset positive Negative Positive
31 Precursor B-ALL Negative ND ND ND ND
32 Precursor T-ALL Negative Negative Negative Negative Weak positive
33 T-ALL Negative ND ND ND ND
34 Precursor B-ALL Negative ND ND ND ND
MPO, myeloperoxidase; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia/lymphoma; ND, not done.
∗AML, t(8;21)(q22;q22) under the new WHO classification.
†Acute promyelocytic leukemia under the new WHO classification.
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Immunohistochemical stains other than CD163
were performed prior to inclusion of cases in the
study. The original diagnoses were confirmed by
histopathologic review by two pathologists (PH and
LM). All AML cases collected for this study were from
our pathology archives and were classified using the
French-American-British (FAB) system at the time of
the original diagnoses. Therefore, we have utilized
this classification in the current study. According
to the current World Health Organization (WHO)
guidelines,1 we found that the majority of cases
would fall under the category of AML, not otherwise
specified. There were two exceptions: one case of
AML-M3v fits best as acute promyelocytic leukemia
and one AML-M2 would be classified as AML with
t(8;21)(q22;q22) under the new WHO guidelines (see
Table 1).
The unstained slides were stained with CD163
antibody, as previously described.9 Briefly, 4 μm
thick unstained sections were pretreated with
Ventana CC1 solution (pH 8.0) for antigen retrieval
and were incubated with NCL-CD163 monoclonal
antibody (clone 10D6, 1 : 50 dilution; Vision
Biosystems, Norwell, MA, USA) using a Ventana
Benchmark XT system (Ventana Medical Systems,
Tucson, AZ, USA). The UltraVision System and
a 3,3′-diaminobenzidine chromagen were used for
detection.
The staining pattern and intensity of CD163 were
assessed on each slide. Cytoplasmic and/or membra-
nous staining for CD163 in at least 10% of tumor cells
was considered positive. Entrapped dendritic cells or
macrophages were not considered when determining
positivity. The percentage of tumor cells labeled was
recorded as one of three categories: <10% (negative),
10–50% and >50%.
Results
As previously described, CD163 labeled dermal
dendritic cells in normal skin (Fig. 1A).9,12 The results
of CD163 staining in LC cases are summarized in
Tables 1 and 2. In many cases, additional markers for
Fig. 1. CD163 expression in leukemia cutis (LC). A) CD163 labels dermal dendritic cells in normal skin. B) CD163 expression in myeloid LC
with monocytic differentiation. C) Myeloid LC without monocytic differentiation normally does not express CD163. D) CD163 is absent in
LC associated with ALL.
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Table 2. Summary of immunohistochemistry results in LC by various
markers∗
Diagnosis CD163 CD68 Lysozyme MPO CD43
AML-M4 4/11 (36%) 7/7 7/8 8/10 10/10
AML-M5 3/6 (50%) 2/3 4/5 4/5 5/5
AML-M4–5 8/18 (44%) 9/11 12/14 11/16 16/16
AML, other
than M4–5
1/10 (10%) 0/1 1/4 4/5 6/6
AML, all 9/28 (32%) 9/12 13/18 15/21 22/22
ALL 0/6 (0%) 0/1 1/2 0/2 2/2
MPO, myeloperoxidase; AML, acute myeloid leukemia; ALL, acute
lymphoblastic leukemia/lymphoma.
∗For all listed markers, numbers of positive cases are given as a
fraction over total cases stained.
myeloid LC were used alongside CD163 (Tables 1
and 2).
Among cases of myeloid LC, CD163 positivity
was observed in 44% (8/18) of myeloid LCs with
a monocytic component (AML-M4 or AML-M5 in
the FAB classification system) (Fig. 1B). AML-M5
showed a higher probability of CD163 expression
compared with AML-M4 (50 and 36% positivity,
respectively). Among positive cases, there was no
significant difference between AML-M4 and AML-
M5 with respect to staining pattern or intensity.
With one exception (1/10), CD163 was negative in
myeloid LC without a monocytic component (FAB
classification of AML M0-M3 or M6) (Fig. 1C). Of
note, one case of AML-M2 showed strong and diffuse
CD163 positivity. In addition, all six cases of T-
ALL or B-ALL were negative for CD163 expression
(Fig. 1D).
In our dataset, CD163 was 100% specific for the
purpose of distinguishing myeloid LC from LC asso-
ciated with ALL. The expression of CD163 was also
highly specific (90%) for myeloid LC with a mono-
cytic component when compared with myeloid LC
without monocytic differentiation. CD163 showed
low sensitivity (24%) for all myeloid LC and a sen-
sitivity of 44% for myeloid LC with a monocytic
component.
Discussion
Myeloid LC often poses a diagnostic challenge,
particularly in cases of aleukemic LC. Because
morphologic features are rarely adequate for
diagnosis, a precise immunophenotyping is critical.
Standard markers for this purpose include CD68,
MPO, lysozyme or CD43. As the most common types
of myeloid LC are AML-M4 or AML-M5, finding
a reliable monocytic marker will be of particular
utility. The reported sensitivity of CD68 (KP1 or
PG-M1) for AML varies in the literature from 33
to 100%.4,11,13,14 Although PGM1 is regarded as
more specific than KP1, both have been shown
to stain melanomas and other malignancies.4 In
addition, they often stain AMLs without a monocytic
component.4,11,13 Although highly specific for the
myeloid lineage, MPO has been reported to be only
58% sensitive for all myeloid LC,2 and is negative in
many cases with monocytic differentiation.1,3,4 This is
to be expected as MPO is generally strongly expressed
only in leukemias with a prominent granulocytic
component (i.e. AML-M2, AML-M3 and AML-
M4). The monocyte/granulocyte marker lysozyme is
highly sensitive, with expression in 93% of myeloid
sarcomas;15 however, it is frequently negative
in immature monoblasts.1– 3,7,13,14,16,17 CD43 is
sensitive for AML, but is also expressed in a
large percentage of B-cell and T-cell lymphomas.1,18
Ultimately, because no marker or combination of
markers is completely sensitive or specific, additional
markers are often desirable to increase diagnostic
confidence in cases of myeloid LC.
CD163 is an endocytic receptor responsible
for scavenging haptoglobin–hemoglobin complexes6
and its expression is largely restricted to cells of
the monocytic/histiocytic lineage.5 Recent studies
showed the expression of CD163 in tumors derived
from monocytes/histiocytes, including AML with
monocytic differentiation.4,5 Moreover, Garcia et al.
showed that CD163 was less sensitive (49%) than
CD68 (81%), but was slightly more specific (89%)
than CD68 (83%) for the presence of monocytic
differentiation in AMLs of bone marrow.7 Recently,
Cronin et al. presented a large study of CD163
in myeloid LC11 and reported 25% sensitivity for
myeloid LC. Among seven positive cases, three
were acute monocytic leukemia and two were
associated with chronic myelomonocytic leukemia.
In agreement with their observations, we found
that the overall sensitivity of CD163 for myeloid
LC in general was 32%. The slight difference in
sensitivity between Cronin et al.’s study and ours
could be because of the higher proportion of cases
with monocytic differentiation in our study group.
We showed that CD163 had a sensitivity of
44% for detecting myeloid LC with monocytic
differentiation, which correlates well with Garcia
et al.’s findings.7 The sensitivity we observed is lower
than the sensitivity (60%) reported by Cronin et al.,
in part because those authors included only acute
monocytic leukemia in the calculation.11 Moreover,
we found that CD163 was slightly more likely to
be expressed in AML-M5 than AML-M4, probably
as a result of greater monocytic component in the
AML-M5. Similarly, a previous study in leukemic
blasts from peripheral blood has shown that CD163
is more frequently expressed in leukemic cells
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of AML-M5 than AML-M4, although this study
showed a much greater difference between the two
(84 and 25%, respectively) than ours.8
Interestingly, we found 1 of 10 myeloid LCs
without monocytic differentiation stained strongly
for CD163. CD163 immunoreactivity has been pre-
viously reported in occasional AMLs without mono-
cytic differentiation.7,8,11 Flow cytometry of bone
marrow in this case showed a CD13+/CD14+
monocytic cell population. As monocytic differen-
tiation is associated with a greater propensity for
extramedullary tumor formation in AML, it is pos-
sible that the skin infiltrate in this case was enriched
for cells with monocytic differentiation.
As indicated in Table 2, no single marker was
positive in all cases of myeloid LC. Given the
high specificity of CD163 for myeloid LC with
monocytic differentiation, as well as the observa-
tion that no marker is 100% sensitive, an opti-
mal approach toward immunophenotyping potential
cases of myeloid LC would be to combine CD163
with CD68, MPO, lysozyme and CD43 (with addi-
tional markers as needed), in order to maximize both
specificity and sensitivity.
It is important to note that CD163 may be
expressed in other diseases, including Langerhans
cell histiocytosis.9 A true diagnostic dilemma arises
when attempting to distinguish myeloid LC from
histiocytoid Sweet’s syndrome.19 Our preliminary
data (unpublished observation) indicates that CD163
may not be helpful for this purpose. The find-
ing is unsurprising, as CD163 does not distinguish
between mature and immature cells of the mono-
cytic/histiocytic lineage.
In summary, CD163 represents an important
addition to an immunohistochemical panel for diag-
nosing myeloid LC with monocytic differentiation,
given its high specificity for cells of monocytic lin-
eage. However, CD163 is only modestly sensitive for
myeloid LC and therefore should not be used alone
for diagnosis.
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